blank
blank

Fair Market Value for Charities in Partnership Work

1:1
Charities face increasing demands from all sectors to support patient and public involvement (PPI) and to work in partnerships. Partnership work uses funds and resources. Charities must manage these costs to ensure financial sustainability.

This guidance, created by a coalition of health charities, including Health Research Charities Ireland and UK-based organisations Cancer 52, the Patient Information Forum (PIF), the Charities Research Involvement Group, and the National Rheumatoid Arthritis Society, is designed to help charities and partners calculate Fair Market Value (FMV) when charities decide to work in partnership and to charge for these activities.

Charities have huge value as partners. It is critical this value is understood and recognised in the process of setting FMV. Our aim is to support the independence of charities and increase transparency about payment. For charities partnership work to continue and grow, there must be fair and transparent payment which contributes to the sustainability of the sector.

Acces this publication
Captura de pantalla 2026-05-14 093636

Year of publication

2026

Author

HRCI & Sasha Daly – Interim CEO, Cancer 52 Jane Lyons –Former CEO Cancer 52 Bec Hanley – Charities Research Involvement Group Dr Avril Kennan – CEO, Health Research Charities Ireland Clare Jacklin – Former CEO, NRAS Peter Foxton – CEO, NRAS Sophie Randall – Director, PIF Sheena Campbell – Communications Manager, PIF

You might also be interested in

2

ERDERA launches Clinical Trial Call 2026 to advance early‑phase clinical trials for rare diseases

ERDERA (the European Rare Diseases Research Alliance) has opened its Clinical Trial Call to support multinational early-phase clinical trials in rare diseases. The call will fund studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.
ECRD 2026

ECRD 2026 in Prague strengthens the push for a coordinated EU Action Plan on rare diseases

On 3–4 June, EURORDIS–Rare Diseases Europe and Orphanet convened the rare disease community at ECRD 2026 in Prague around a shared call for coordinated European action, including the forthcoming European Blueprint for Rare Diseases.
ERDERA Open Academy 2026

Open Academy x ERDERA Schools in Barcelona strengthen practical links between patient advocacy and rare disease research

The 2026 Open Academy x ERDERA Schools in Barcelona brought patient advocates and early-career researchers together for practical training on medicines development, translational research and meaningful participation in rare disease research.
Sveriges riksdag (house of parlament).

Sweden adopts first national strategy for rare health conditions

Sweden has adopted its first national strategy for rare health conditions, aiming to improve coordination, equity and access to care between 2026 and 2030.

ERDERA's

search form